Nan Mao
Impact in
- Nephrology top 5%
- Renal Diseases and Glomerulopathies
- Chronic Kidney Disease and Diabetes
- Parathyroid Disorders and Treatments
- Gout, Hyperuricemia, Uric Acid
-
- Sirtuins and Resveratrol in Medicine
Papers in
-
- Ginseng Biological Effects and Applications 4
- RNA modifications and cancer 2
- Ubiquitin and proteasome pathways 1
-
- Gout, Hyperuricemia, Uric Acid 2
- Co-authors
- Junming Fan (3 shared papers)Sichong Ren (7 shared papers)Junming Fan (7 shared papers)Xinli Shi (4 shared papers)Ruizhi Tan (2 shared papers)Ji Wen (2 shared papers)Li Wang (1 shared paper)Honglian Wang (2 shared papers)
In The Last Decade
Nan Mao
29 papers receiving 310 citations
Peers
Comparison fields: 5 of 72
- Nephrology 76
- Geriatrics and Gerontology 13
- Pharmacology 16
- Epidemiology 58
- Biological Psychiatry 4
Countries citing papers authored by Nan Mao
This map shows the geographic impact of Nan Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Mao more than expected).
Fields of papers citing papers by Nan Mao
This network shows the impact of papers produced by Nan Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Mao. The network helps show where Nan Mao may publish in the future.
Co-authors
The 25 scholars most cited alongside Nan Mao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 44 | |
| 2 | 2015 | 30 | |
| 3 | 2022 | 30 | |
| 4 | 2014 | 27 | |
| 5 | 2022 | 23 | |
| 6 | 2016 | 21 | |
| 7 | 2021 | 13 | |
| 8 | 2023 | 13 | |
| 9 | 2014 | 12 | |
| 10 | 2014 | 11 | |
| 11 | 2012 | 10 | |
| 12 | 2019 | 10 | |
| 13 | 2024 | 9 | |
| 14 | 2023 | 8 | |
| 15 | 2023 | 7 | |
| 16 | 2022 | 7 | |
| 17 | 2023 | 6 | |
| 18 | 2024 | 5 | |
| 19 | 2023 | 5 | |
| 20 | 2020 | 4 |
About Nan Mao
Nan Mao is a scholar working on Molecular Biology, Nephrology, Pulmonary and Respiratory Medicine, Surgery and Oncology, having authored 35 papers that have together received 312 indexed citations. Recurring topics across this work include Ginseng Biological Effects and Applications (4 papers), Gout, Hyperuricemia, Uric Acid (2 papers), Autophagy in Disease and Therapy (2 papers), RNA modifications and cancer (2 papers), Risk and Safety Analysis (1 paper), Ubiquitin and proteasome pathways (1 paper), Vascular Procedures and Complications (1 paper) and Renal and Vascular Pathologies (1 paper). The work is most often cited by research in Nephrology (76 citations), Geriatrics and Gerontology (13 citations), Pharmacology (16 citations), Epidemiology (58 citations) and Biological Psychiatry (4 citations). Nan Mao has collaborated with scholars based in China, Germany and Belgium. Frequent co-authors include Junming Fan, Sichong Ren, Junming Fan, Xinli Shi, Ruizhi Tan, Ji Wen, Li Wang, Honglian Wang, Jing Xie and Yixuan Zheng. Their work appears in journals such as Renal Failure, Acta Pharmacologica Sinica, BMC Cancer, Frontiers in Pharmacology and Journal of Diabetes and its Complications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.